Literature DB >> 26406149

Renal-Cell Cancer--Targeting an Immune Checkpoint or Multiple Kinases.

David I Quinn1, Primo N Lara.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26406149     DOI： 10.1056/NEJMe1511252

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  11 in total

1.  Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithms.

Authors:  C Rothermundt; J von Rappard; T Eisen; B Escudier; V Grünwald; J Larkin; D McDermott; J Oldenburg; C Porta; B Rini; M Schmidinger; C N Sternberg; P M Putora
Journal:  World J Urol       Date:  2016-08-03       Impact factor: 4.226

Review 2.  Metabolic reprogramming in clear cell renal cell carcinoma.

Authors:  Hiromi I Wettersten; Omran Abu Aboud; Primo N Lara; Robert H Weiss
Journal:  Nat Rev Nephrol       Date:  2017-05-08       Impact factor: 28.314

3.  Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma.

Authors:  Ashley Orillion; Ayumi Hashimoto; Nur Damayanti; Li Shen; Remi Adelaiye-Ogala; Sreevani Arisa; Sreenivasulu Chintala; Peter Ordentlich; Chingai Kao; Bennett Elzey; Dmitry Gabrilovich; Roberto Pili
Journal:  Clin Cancer Res       Date:  2017-07-11       Impact factor: 12.531

Review 4.  The Nephrologist's Tumor: Basic Biology and Management of Renal Cell Carcinoma.

Authors:  Susie L Hu; Anthony Chang; Mark A Perazella; Mark D Okusa; Edgar A Jaimes; Robert H Weiss
Journal:  J Am Soc Nephrol       Date:  2016-03-09       Impact factor: 10.121

Review 5.  Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice.

Authors:  Richard W Joseph; Gurkamal Chatta; Ulka Vaishampayan
Journal:  Urol Oncol       Date:  2017-03-02       Impact factor: 3.498

Review 6.  Precision medicine from the renal cancer genome.

Authors:  Yasser Riazalhosseini; Mark Lathrop
Journal:  Nat Rev Nephrol       Date:  2016-10-03       Impact factor: 28.314

7.  Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma.

Authors:  Kyu Seo Kim; Rishi R Sekar; Dattatraya Patil; Michelle A Dimarco; Haydn T Kissick; Mehmet A Bilen; Adeboye O Osunkoya; Viraj A Master
Journal:  Oncoimmunology       Date:  2018-01-10       Impact factor: 8.110

8.  Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma.

Authors:  Witold Wiecek; Helene Karcher
Journal:  PLoS One       Date:  2016-06-06       Impact factor: 3.240

9.  Inhibiting tryptophan metabolism enhances interferon therapy in kidney cancer.

Authors:  Josephine F Trott; Jeffrey Kim; Omran Abu Aboud; Hiromi Wettersten; Benjamin Stewart; Grace Berryhill; Francisco Uzal; Russell C Hovey; Ching-Hsien Chen; Katie Anderson; Ashley Graef; Aaron L Sarver; Jaime F Modiano; Robert H Weiss
Journal:  Oncotarget       Date:  2016-10-11

Review 10.  Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential.

Authors:  Melissa Bersanelli; Sebastiano Buti
Journal:  Ther Adv Med Oncol       Date:  2017-08-02       Impact factor: 8.168
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.